Chiltern International United Kingdom

Established in 1982, Chiltern is a leading global clinical CRO offering specialized services in all phases of oncology, hematology and a range of other therapeutic areas (respiratory, ophthalmology, dermatology, etc.), together with global sourcing and functional service provider (FSP) solutions. Chiltern’s 3.700 people work in more than 40 countries and offer expertise, engagement and tailored, responsive solutions to meet the demands of biotech and pharmaceutical partners of all sizes.

Website:
www.chiltern.com
Organisation type
Ms Andrea Cotton-Berry
LinkedIn logo Executive Director, Client Services 
Ms Frances Murphy
LinkedIn logo Director, Client Services 
Ms Ivana Galjer
LinkedIn logo Director, Client Services 
Mr John O'Brien
LinkedIn logo Senior Director, Business Development 
Dr Jan de Witt
LinkedIn logo Vice President, Medical Affairs 

Clinical Network Services (CNS) Ltd United Kingdom

Clinical Network Services (CNS) is an integrated service group focused on product development headquartered in Australia with offices in New Zealand, the UK and the USA.

CNS creates value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner.

CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with our committed, highly experienced Australian/New Zealand clinical operations and biometrics team.

BioDesk’s expert consultants offer CMC/manufacturing, toxicology, clinical and regulatory affairs strategic advice and guide products efficiently through critical post-discovery development and into the clinic for the first time.

With over 15 years’ experience on more than 300 projects, CNS is one of the most experienced providers within the local market and a partner of choice for biotech companies.

CNS’s small-medium size is considered a big advantage when relating to similar sized clients, though CNS takes a global development/ regulatory approach to ensure value is strategically added at every stage of the product development life cycle.

Further information about CNS and its intelligent development services can be found at www.clinical.net.au

Organisation type
Mr Paul Cronin
LinkedIn logo Director, Business Development 
Mr Russell Neal
LinkedIn logo Managing Director 

Datatrial United Kingdom

Datatrial is a clinical biometrics and technology organisation specialising in complete study delivery; from our flexible and intuitive platform of technologies to our services and consulting. We offer a full range of services including Data Management, Statistics and Medical Writing.

Our innovative nowEDC™ solution allows you to deliver data capture, verification and validation, query management, data extract, IWRS and real-time reporting in one integrated system.

We are a service-driven company; our goal is to meet timelines, exceed expectations through our proactive approach, and be responsive to and collaborative with our customers. Communication, service and quality are critical to a successful clinical study, while always keeping the patient in mind.

Miss Amy Wright
LinkedIn logo Customer Relationship Manager 
Dr Emma Banks
LinkedIn logo CEO 

Fusion Antibodies Ltd United Kingdom

Fusion Antibodies offer a range of highly competitive services in the antibody drug discovery and development space. We specialise in production of monoclonal antibodies, antibody engineering, antibody humanization, antibody sequencing, stable cell line development and antibody expression. With 15+ years of experience in the medical research industry, including two of our own Antibodies in clinical and pre-clinical trials, Fusion Antibodies is a world-wide industry leader in therapeutic and diagnostic antibody development.

Keywords
Antibody Humanization, Antibody Sequencing, Cell Line Development
Organisation type
Dr Paul Kerr
LinkedIn logo Managing Director 

Illingworth Research Ltd United Kingdom

Illingworth Research is a full service clinical CRO with experience across all phases of development from Phase I / proof of concept studies to post-marketing studies for small molecules, biotechnology products, medical devices and diagnostics. With a network of clinical infrastructure covering most therapeutic areas varying from clinical research units, primary, secondary and tertiary care sites across Europe and with partners in North America and Australasia, Illingworth has the capability to deliver large multi-centre global studies on time and within budget. Illingworth also provides research nurses for patient homecare to support studies for optimisation of patient retention and compliance. Illingworth also offers a medical photography service.

Dr Julian Cooper
LinkedIn logo Director of Business Development and Proposals 

SYNthesis United Kingdom

SYNthesis Research has established a number of R&D collaborations which have generated novel IP which is now available for partnering. SYNthesis Research's sister company, SYNthesis med chem, is a chemistry-focussed contract research organisation that carries out custom synthesis and medicinal chemistry projects.

Organisation type
Mr Simon Bury
LinkedIn logo Head of Business Development 
Prof Andrew Wilks
LinkedIn logo Chairman & co-founder